Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C

References

• Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–1877.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;369:678–679.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001.
   PubMed Web of Science ®Google Scholar
• Lam B, Henry L, Younossi Z. Sofosbuvir (Sovaldi) for the treatment of hepatitis C. Expert Rev Clin Pharmacol. 2014 Sep;7(5):555–566. Epub 2014 Jun 11. DOI:10.1586/17512433.2014.928196
   PubMed Web of Science ®Google Scholar
• Gilead Sciences. Highlights of prescribing information – Harvoni. [ cited 2016 Aug 18]. Available from https://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf
   Google Scholar
• Sundaram V, Kowdley KV. Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection. Hepat Med. 2016 Jun 28;8:75–80. eCollection 2016. DOI:10.2147/HMER.S63125
   PubMedGoogle Scholar
• Fazel Y, Lam B, Golabi P, et al. Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. Expert Opin Drug Saf. 2015 Aug;14(8):1317–1326. Epub 2015 Jun 4. DOI:10.1517/14740338.2015.1053868
   PubMed Web of Science ®Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–1898.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–1888.
   PubMed Web of Science ®Google Scholar
• Alqahtani SA, Afdhal N, Zeuzem S, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials. Hepatology. 2015 Jul;62(1):25–30. Epub 2015 Jun 1. DOI:10.1002/hep.27890
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014 Apr 17;370(16):1483–1493. Epub 2014 Apr 11. DOI:10.1056/NEJMoa1316366
   PubMed Web of Science ®Google Scholar
• American Association for the Study of Liver Diseases; Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. HCV Guidance. [ cited 2016 Jul 28]. Available from. http://hcvguidelines.org/sites/default/files/HCV-guidance_March_2016_c1.pdf
   Google Scholar
• Younossi ZM, Park H, Gordon SC, et al. Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. Am J Manag Care. 2016 May;22(6 Spec No.):SP205- SP11.
   PubMed Web of Science ®Google Scholar
• Curry MP, Bacon B, Dieterich D, et al. Effectiveness of 8 or 12 week LDV/SOF in treatment-naïve patients with non-cirrhotic, genotype 1 hepatitis C: real-world experience from the TRIO network. Presented at: 66th Annual Meeting of the American Association for the Study of Liver Diseases; 2015 Nov 13-17; San Francisco, CA.
   Google Scholar
• Backus L, Belperio PS, Shahoumian TA, et al. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology. 2016 Aug;64(2):405–414. Epub 2016 Jun 7. DOI:10.1002/hep.28625
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control- Health Related Quality of Life. [ cited 2014 Feb 27]. Available from http://www.cdc.gov/HRQoL/concept.htm
   Google Scholar
• van der Plas SM, Hansen BE, de Boer JB, et al. Generic and disease-specific health related quality of life of liver patients with various aetiologies: a survey. Qual Life Res. 2007 Apr;16(3):375–388.
   PubMed Web of Science ®Google Scholar
• Gnanasakthy A, Mordin M, Clark M, et al. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health. 2012 May;15(3):437–442.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Boparai N, Price LL, et al. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol. 2001 Jul;96(7):2199–2205.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Guyatt G, Kiwi M, et al. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999 Aug;45(2):295–300.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology. 2007 Mar;45(3):806–816. Review. PubMed PMID: 17326207
   PubMed Web of Science ®Google Scholar
• Afendy A, Kallman JB, Stepanova M, et al. Predictors of health-related quality of life in patients with chronic liver disease. Aliment Pharmacol Ther. 2009 Sep 1;30(5):469–476.
   PubMed Web of Science ®Google Scholar
• Vera-Llonch M, Martin M, Aggarwal J, et al. Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Aliment Pharmacol Ther. 2013 Jul;38(2):124–133. Epub 2013, Jun 3. PubMed PMID: 23725204. DOI:10.1111/apt.12354
   PubMed Web of Science ®Google Scholar
• Loria A, Escheik C, Gerber NL, et al. Quality of life in cirrhosis. Curr Gastroenterol Rep. 2013 Jan;15(1):301. DOI:10.1007/s11894-012-0301-5
   PubMedGoogle Scholar
• Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res. 2001;10(5):405-13; discussion 415-20.
   Web of Science ®Google Scholar
• Webster K, Odom L, Peterman A, et al. The functional assessment of chronic illness therapy (FACIT) measurement system: validation of version 4 of the core questionnaire. Qual Life Res. 1999;8(7):604.
   Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4:353–365.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Singer ME, Mir HM, et al. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol. 2014;60(3):530–537. DOI:10.1016/j.jhep.2013.11.009.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Nader F, et al. The patient’s journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life. Aliment Pharmacol Ther. 2015 Aug;42(3):286–295. Epub 2015 Jun 9. DOI:10.1111/apt.13269
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Henry L, et al. Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens. Medicine (Baltimore). 2016 Jul;95(28):e4151. DOI:10.1097/MD.0000000000004151
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Henry L, et al. Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus. J Viral Hepat. 2016 Aug;23(8):623–630. Epub 2016 Mar 14. DOI:10.1111/jvh.12528
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, −2, and −3 clinical trials. Hepatology. 2015 Jun;61(6):1798–1808. Epub 2015 Mar 18. DOI:10.1002/hep.27724
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015 Aug;63(2):337–345. Epub 2015 Mar 17. DOI:10.1016/j.jhep.2015.03.014
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Sulkowski M, et al., Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. J Viral Hepat. 2016 Jun;13. [Epub ahead of print]. DOI:10.1111/jvh.12554
   PubMedGoogle Scholar
• Younossi ZM, Bacon BR, Dieterich DT, et al. Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network. J Viral Hepat. 2016 Jun;23(6):447–454. Epub 2016 Feb 3. DOI:10.1111/jvh.12506
   PubMed Web of Science ®Google Scholar
• World Health Organization. Blood Safety. Key global fact and figures in 2001. [ cited 2016 Sept 21]. Available from:: http://www.who.int/bloodsafety/global_database/GDBS_Summary_Report_2011.pdf?ua=1
   Google Scholar
• Younossi ZM, Stepanova M, Henry L, et al. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. Am J Gastroenterol. 2016 Jun;111(6):808–816. Epub 2016 Mar 29. DOI:10.1038/ajg.2016.99
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Jiang Y, Smith NJ, et al. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: insights from a work productivity economic model from the United States. Hepatology. 2015 May;61(5):1471–1478. Epub 2015 Mar 23. DOI:10.1002/hep.27757
   PubMed Web of Science ®Google Scholar
• Ward JW Placing Nation on the Path toward the Elimination of Hepatitis C. [ cited 2016 Sept 22]. Available from http://nationalacademies.org/hmd/~/media/Files/Activity%20Files/PublicHealth/HepatitisBandC/1-November2015/1-%20John%20Ward.pdf
   Google Scholar
• Markov XS. Modelling in healthcare economic evaluations. Chin J Evid-based Med. 2007;7(10):750–757.
   Google Scholar
• Davis KL, Mitra D, Medjedovic J, et al. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol. 2011 Feb;45(2):e17–24. DOI:10.1097/MCG.0b013e3181e12c09
   PubMedGoogle Scholar
• Stepanova M, Kanwal F, El-Serag HB, et al. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology. 2011 Mar;53(3):737–745. Epub 2011 Feb 11. DOI:10.1002/hep.24131
   PubMed Web of Science ®Google Scholar
• Sibley A, Han KH, Abourached A, et al. The present and future disease burden of hepatitis C virus infections with today’s treatment paradigm – volume 3. J Viral Hepat. 2015 Dec;22(Suppl 4):21–41. DOI:10.1111/jvh.12476.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Singer ME, McHutchison JG, et al. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology. 1999 Nov;30(5):1318–1324.
   PubMed Web of Science ®Google Scholar
• Stepanova M, Younossi ZM. Interferon-free regimens for chronic hepatitis C: barriers due to treatment candidacy and insurance coverage. Dig Dis Sci. 2015 Nov;60(11):3248–3251. Epub 2015 May 19. DOI:10.1007/s10620-015-3709-6
   PubMed Web of Science ®Google Scholar
• Deuffic-Burban S, Schwarzinger M, Obach D, et al. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). J Hepatol. 2014;61(1):7–14. DOI:10.1016/j.jhep.2014.03.011.
   PubMed Web of Science ®Google Scholar
• Hagan LM, Yang Z, Ehteshami M, et al. All-oral, interferon free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat. 2013;20(12):847–857. DOI:10.1111/jvh.12111.
   PubMed Web of Science ®Google Scholar
• Poonsapaya JM, Einodshofer M, Kirkham HS, et al. New all oral therapy for chronic hepatitis C virus (HCV): a novel long-term cost comparison. Cost Eff Resour Alloc. 2015 Oct 6;13:17. eCollection 2015. DOI:10.1186/s12962-015-0043-y
   PubMed Web of Science ®Google Scholar
• Saab S, Virabhak S, Parisé H, et al. Cost-effectiveness of genotype 1 chronic hepatitis C virus treatments in patients coinfected with human immunodeficiency virus in the United States. Adv Ther. 2016 Aug;33(8):1316–1330. Epub 2016 Jun 24. DOI:10.1007/s12325-016-0362-1
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Park H, Saab S, et al. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015;41(6):544–563. DOI:10.1111/apt.13081.
   PubMed Web of Science ®Google Scholar
• Younossi Z. What is the ethical responsibility of a provider when prescribing the new direct-acting antiviral agents to patients with hepatitis C infection? Clinic Liv Dis. 2015;6(5):117–119.
   Google Scholar
• Younossi ZM, LaLuna LL, Santoro JJ, et al. Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study. BMC Gastroenterol. 2016;16:45. DOI:10.1186/s12876-016-0438-z.
   PubMed Web of Science ®Google Scholar
• Allison WE, Chiang W, Rubin A, et al. Hepatitis C virus infection in the 1945-1965 birth cohort (baby boomers) in a large urban ED. Am J Emerg Med. 2016 Apr;34(4):697–701. Epub 2015 Dec 29. DOI:10.1016/j.ajem.2015.12.072
   PubMed Web of Science ®Google Scholar
• WHO authors. Combating hepatitis B and C to reach elimination by 2030 (Report of 2016). cited 2016 Sep 22]. Available from http://apps.who.int/iris/bitstream/10665/206453/1/WHO_HIV_2016.04_eng.pdf?ua=1
   Google Scholar
• Waheed Y. Hepatitis C eradication: a long way to go. World JGastroenterol. 2015;21(43):12510–12512. DOI:10.3748/wjg.v21.i43.12510
   PubMed Web of Science ®Google Scholar
• Jayasekera CR, Barry M, Roberts LR, et al. Treating hepatitis C in lower-income countries. N Engl J Med. 2014;370:1869–1871. PMID: 24720680. DOI:10.1056/NEJMp1400160]
   PubMed Web of Science ®Google Scholar
• Graham CS, Swan T. A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Res. 2015 Jul;119:89–96. Epub 2015 Jan 20. DOI:10.1016/j.antiviral.2015.01.004
   PubMed Web of Science ®Google Scholar
• Panduro A, Roman S. Need of righteous attitudes towards eradication of hepatitis C virus infection in Latin America. World J Gastroenterol [Internet]. 2016 [cited 2016 Jun 14];22(22):5137–5142. DOI:10.3748/wjg.v22.i22.5137.
   PubMed Web of Science ®Google Scholar
• Solomon SS, Mehta SH, Srikrishnan AK, et al. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study. Lancet Infect Dis. 2015;15:36–45. PMID: 25486851. DOI:10.1016/S1473-3099(14)71045-X]
   PubMed Web of Science ®Google Scholar
• Nelson P, Mathers B, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571–583.
   PubMed Web of Science ®Google Scholar
• Werner CR, Schwarz JM, Egetemeyr DP, et al. Second-generation direct-acting-antiviral hepatitis C virus treatment: efficacy, safety, and predictors of SVR12. World J Gastroenterol [Internet]. 2016 [cited 2016 Sep 21];22(35):8050–8059. DOI:10.3748/WJG.v22.i35.8050.
   PubMed Web of Science ®Google Scholar